The Role of New Compounds in Psychedelic Therapy - Ronan Levy, Co-Founder of Field Trip Health and Reunion Neuroscience

As researchers continue to explore therapeutic applications of existing psychedelic drugs such as LSD and psilocybin, there's been a parallel effort to create new compounds that produce the same beneficial effects, but that come without the lengthy protocols and regulatory obstacles attached to those currently criminalized substances. "If you could develop new molecules that were more targeted and shorter acting, you may actually be able to create medicines as potent as the existing ones, but administratively and medically more efficient so we can reach more people," says Ronan Levy, a serial entrepreneur in the space. After a foray into creating a business model for ketamine-assisted therapy, Levy is now looking to support the community of millions of people who are already using psychedelics in various capacities through his Non-Ordinary Therapy Company instead of providing the therapeutic experience directly. “Wherever you're having your psychedelic experiences, that's wonderful. We're there to help you get the maximum impact from your sessions.” Join host Shiv Gaglani for this fascinating conversation about responsibly pushing regulatory boundaries, whether hallucinatory effects are essential to therapeutic benefit, and the rapid pace of change in a field that holds the potential to, as Levy puts it, “displace most forms of mental health care currently provided.” Mentioned in this episode: Non-Ordinary Therapy CompanyThe Ketamine Breakthrough (book) If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast